Skip to content

Study · Animal study (in vivo) · mouse · 2026

12 results

MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia.

Jamnick NA, Livingston PD, Gammon CJ, Weinzierl NM, Novinger LJ, Bonetto A

Frontiers in medicine25 May 2026

PMID42266945 (opens in a new tab)DOI10.3389/fmed.2026.1838178 (opens in a new tab)PepBankPUB-42266945
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with C26 cachexia, MOTS‑c did not prevent total body weight loss.

    In plain wordsIn mice with cancer cachexia, MOTS‑c did not stop overall body weight loss.

    Peptide
    MOTS-c
    Outcome
    No significant changeTotal body weight loss in C26 cachexia
    Study

    mousen: not reported in source

    C26 cancer cachexia
    Outcome group
    Body weight · Musculoskeletal
    Studied dose
    15 mg/kg twice daily · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Although MOTS-c did not prevent total body weight or fat loss
    1 context sentence
    Summary · context
    In vivo, male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with C26 cachexia, MOTS‑c did not prevent fat loss.

    In plain wordsIn mice with cancer cachexia, MOTS‑c did not stop loss of body fat.

    Peptide
    MOTS-c
    Outcome
    No significant changeFat loss in C26 cachexia
    Study

    mousen: not reported in source

    C26 cancer cachexia
    Outcome group
    Body weight · Musculoskeletal
    Studied dose
    15 mg/kg twice daily · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Although MOTS-c did not prevent total body weight or fat loss
    1 context sentence
    Summary · context
    In vivo, male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with C26 cachexia, MOTS‑c preserved quadriceps weight, 12% higher than in C26 vehicle mice (p < 0.05).

    In plain wordsIn mice with cancer cachexia, MOTS‑c helped keep thigh muscle weight compared with untreated mice.

    Peptide
    MOTS-c
    Outcome
    IncreaseQuadriceps weight
    Study

    mousen: not reported in source

    C26 cancer cachexia
    Comparator
    C26 vehicle
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    15 mg/kg twice daily · intraperitonealAs given in this study (mouse).

    Measurements

    Quadriceps weight difference
    12%
    vs C26 vehicle

    Source sentences

    Summary
    Although MOTS-c did not prevent total body weight or fat loss, it significantly preserved skeletal muscle mass, rescuing quadriceps weight (+12% vs. C26 vehicle; p < 0.05) and trending toward protection of gastrocnemius mass and EDL function.
    1 context sentence
    Summary · context
    In vivo, male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with C26 cachexia, MOTS‑c showed only a trend toward protecting gastrocnemius mass.

    In plain wordsIn mice with cancer cachexia, MOTS‑c showed only a possible trend toward protecting calf muscle mass.

    Peptide
    MOTS-c
    Outcome
    No significant changeGastrocnemius mass
    Study

    mousen: not reported in source

    C26 cancer cachexia
    Comparator
    C26 vehicle
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    15 mg/kg twice daily · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Although MOTS-c did not prevent total body weight or fat loss, it significantly preserved skeletal muscle mass, rescuing quadriceps weight (+12% vs. C26 vehicle; p < 0.05) and trending toward protection of gastrocnemius mass and EDL function.
    1 context sentence
    Summary · context
    In vivo, male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with C26 cachexia, MOTS‑c showed only a trend toward protecting EDL muscle function.

    In plain wordsIn mice with cancer cachexia, MOTS‑c showed only a possible trend toward protecting EDL muscle function.

    Peptide
    MOTS-c
    Outcome
    No significant changeEDL muscle function
    Study

    mousen: not reported in source

    C26 cancer cachexia
    Comparator
    C26 vehicle
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    15 mg/kg twice daily · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Although MOTS-c did not prevent total body weight or fat loss, it significantly preserved skeletal muscle mass, rescuing quadriceps weight (+12% vs. C26 vehicle; p < 0.05) and trending toward protection of gastrocnemius mass and EDL function.
    1 context sentence
    Summary · context
    In vivo, male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with C26 cachexia, MOTS‑c attenuated the cachexia-induced upregulation of Atrogin-1.

    In plain wordsIn mice with cancer cachexia, MOTS‑c reduced the rise in Atrogin-1, a muscle breakdown gene.

    Peptide
    MOTS-c
    Outcome
    DecreaseAtrogin-1 upregulation
    Study

    mousen: not reported in source

    C26 cancer cachexia
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    15 mg/kg twice daily · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Cachexia-induced upregulation of Atrogin-1 (+8.6-fold) and MuRF1 (+16-fold) was attenuated by MOTS-c, accompanied by increased inhibitory pFOXO1 (+80%), reduced pFOXO3a (-39%), and partial restoration of PGC-1α protein (+143%).
    1 context sentence
    Summary · context
    In vivo, male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice with C26 cachexia, MOTS‑c attenuated the cachexia-induced upregulation of MuRF1.

    In plain wordsIn mice with cancer cachexia, MOTS‑c reduced the rise in MuRF1, a muscle breakdown gene.

    Peptide
    MOTS-c
    Outcome
    DecreaseMuRF1 upregulation
    Study

    mousen: not reported in source

    C26 cancer cachexia
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    15 mg/kg twice daily · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Cachexia-induced upregulation of Atrogin-1 (+8.6-fold) and MuRF1 (+16-fold) was attenuated by MOTS-c, accompanied by increased inhibitory pFOXO1 (+80%), reduced pFOXO3a (-39%), and partial restoration of PGC-1α protein (+143%).
    1 context sentence
    Summary · context
    In vivo, male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice with C26 cachexia, MOTS‑c increased inhibitory pFOXO1 by 80%.

    In plain wordsIn mice with cancer cachexia, MOTS‑c raised a signal (pFOXO1) that blocks muscle breakdown.

    Peptide
    MOTS-c
    Outcome
    IncreaseInhibitory pFOXO1
    Study

    mousen: not reported in source

    C26 cancer cachexia
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    15 mg/kg twice daily · intraperitonealAs given in this study (mouse).

    Measurements

    pFOXO1 change
    80%
    MOTS-c

    Source sentences

    Summary
    Cachexia-induced upregulation of Atrogin-1 (+8.6-fold) and MuRF1 (+16-fold) was attenuated by MOTS-c, accompanied by increased inhibitory pFOXO1 (+80%), reduced pFOXO3a (-39%), and partial restoration of PGC-1α protein (+143%).
    1 context sentence
    Summary · context
    In vivo, male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In mice with C26 cachexia, MOTS‑c reduced pFOXO3a by 39%.

    In plain wordsIn mice with cancer cachexia, MOTS‑c lowered pFOXO3a, a muscle breakdown signal, by 39%.

    Peptide
    MOTS-c
    Outcome
    DecreasepFOXO3a
    Study

    mousen: not reported in source

    C26 cancer cachexia
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    15 mg/kg twice daily · intraperitonealAs given in this study (mouse).

    Measurements

    pFOXO3a change
    −39%
    MOTS-c

    Source sentences

    Summary
    Cachexia-induced upregulation of Atrogin-1 (+8.6-fold) and MuRF1 (+16-fold) was attenuated by MOTS-c, accompanied by increased inhibitory pFOXO1 (+80%), reduced pFOXO3a (-39%), and partial restoration of PGC-1α protein (+143%).
    1 context sentence
    Summary · context
    In vivo, male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice with C26 cachexia, MOTS‑c partially restored PGC-1α protein (+143%).

    In plain wordsIn mice with cancer cachexia, MOTS‑c partly restored PGC-1α, a marker of new mitochondria, in muscle.

    Peptide
    MOTS-c
    Outcome
    IncreasePGC-1α protein
    Study

    mousen: not reported in source

    C26 cancer cachexia
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    15 mg/kg twice daily · intraperitonealAs given in this study (mouse).

    Measurements

    PGC-1α protein change
    143%
    MOTS-c

    Source sentences

    Summary
    Cachexia-induced upregulation of Atrogin-1 (+8.6-fold) and MuRF1 (+16-fold) was attenuated by MOTS-c, accompanied by increased inhibitory pFOXO1 (+80%), reduced pFOXO3a (-39%), and partial restoration of PGC-1α protein (+143%).
    1 context sentence
    Summary · context
    In vivo, male mice were inoculated with Colon-26 (C26) carcinoma cells and treated daily with MOTS-c (15 mg/kg/2x Day, i.p.) or vehicle.
  11. 11LabIn vitro (cells)Mechanism

    In differentiated myotubes, MOTS‑c at 50 μM increased PGC-1α mRNA by 84.6%.

    In plain wordsIn muscle cells in the lab, MOTS‑c raised PGC-1α, a marker of new mitochondria, by 84.6%.

    Peptide
    MOTS-c
    Outcome
    IncreasePGC-1α mRNA
    Study

    n: not reported in source

    Differentiated myotubes
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    50 μMAs given in this study.

    Measurements

    PGC-1α mRNA change
    84.6%
    MOTS-c 50 μM

    Source sentences

    Summary
    In vitro, MOTS-c increased PGC-1α mRNA (+84.6%) and AMPK phosphorylation (+103.1%).
    1 context sentence
    Summary · context
    Differentiated myotubes were treated with MOTS-c (50 μM) to assess intracellular signaling.
  12. 12LabIn vitro (cells)Mechanism

    In differentiated myotubes, MOTS‑c at 50 μM increased AMPK phosphorylation by 103.1%.

    In plain wordsIn muscle cells in the lab, MOTS‑c switched on the AMPK energy-sensing pathway, with a 103.1% rise in phosphorylation.

    Peptide
    MOTS-c
    Outcome
    IncreaseAMPK phosphorylation
    Study

    n: not reported in source

    Differentiated myotubes
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    50 μMAs given in this study.

    Measurements

    AMPK phosphorylation change
    103.1%
    MOTS-c 50 μM

    Source sentences

    Summary
    In vitro, MOTS-c increased PGC-1α mRNA (+84.6%) and AMPK phosphorylation (+103.1%).
    1 context sentence
    Summary · context
    Differentiated myotubes were treated with MOTS-c (50 μM) to assess intracellular signaling.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.